Mantle Cell Lymphoma

Sonrotoclax shows promise as a new treatment for relapsed/refractory mantle cell lymphoma, achieving significant response rates in heavily pretreated patients.

The CAR-T treatment GLPG5101 received the FDA's RMAT designation by showing promising efficacy with rapid delivery and low toxicity in mantle cell lymphoma.

In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients with mantle cell lymphoma.

Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle cell lymphoma.

In an interview, Craig A. Portell, MD, offered an in-depth look at sequencing therapies in relapsed/refractory mantle cell lymphoma.

Zanubrutinib, obinutuzumab, and venetoclax delivered promising response and survival data for the treatment of patients with mantle cell lymphoma harboring a TP53 mutation.

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.

The ready-to-use formulation of bortezomib is now an FDA-approved option for patients with multiple myeloma and mantle cell lymphoma.

Acalabrutinib plus bendamustine and rituximab led to a 27% reduction in the risk of disease progression or death in the frontline setting for older patients with mantle cell lymphoma.

A study showed that a treatment regimen called BOVen was safe and effective in producing responses in older patients with mantle cell lymphoma.

The FDA has approved the CAR T-cell therapy liso-cel for the treatment of patients with mantle cell lymphoma.

Acalabrutinib plus bendamustine and rituximab bettered progression-free survival over bendamustine and rituximab alone in patients with untreated mantle cell lymphoma.

In an interview with Targeted Oncology, Julie Chang, MD, discussed the minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma and the key findings from the trial.

Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.

Findings suggest that liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features, who have limited treatment options.

Matthew Matasar, MD, discussed the rationale and findings of the doublet consisting of ibrutinib and venetoclax for the treatment of mantle cell lymphoma.

Julie Chang, MD, discusses the reasoning behind the development of a minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma.

High complete response rates and low incidences of cytokine release syndrome and neurological events were observed when patients with relapsed or refractory mantle cell lymphoma were treated with lisocabtagene maraleucel.

In an interview with Targeted Oncology, Andre Goy, MD, discussed the potential of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory mantle cell lymphoma and how 2 studies provide support for use of the agent in this patient population.

Anita Kumar, MD, discusses findings from the phase 2 study of zanubrutinib, obinutuzumab, and venetoclax in TP53-mutant mantle cell lymphoma presented at ASH 2023.

Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.

Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival and complete response rate.

Treatment with zanubrutinib, obinutuzumab, and venetoclax, also known as BOVen, showed promising safety and efficacy in treatment-naive patients with TP53-mutant mantle cell lymphoma.

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.